Response of metastatic breast cancer to trastuzumab?
- 1 January 2000
- journal article
- Published by Elsevier in The Lancet
- Vol. 355 (9199) , 160-161
- https://doi.org/10.1016/s0140-6736(99)00430-4
Abstract
No abstract availableThis publication has 11 references indexed in Scilit:
- Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic DiseaseJournal of Clinical Oncology, 1999
- Comparison of Fluorescence In Situ Hybridization and Immunohistochemistry for the Evaluation of HER-2/neu in Breast CancerJournal of Clinical Oncology, 1999
- Biotechnology UpdateJournal of the American Pharmaceutical Association, 1999
- Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancerClinical Therapeutics, 1999
- Using HER2 to Choose Chemotherapy in Breast Cancer: Is It Ready for the Clinic?JNCI Journal of the National Cancer Institute, 1999
- HER-2/neuTesting Comes of AgeAmerican Journal of Clinical Pathology, 1999
- Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment.Journal of Clinical Oncology, 1998
- Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer.Journal of Clinical Oncology, 1996
- Monoclonal antibodies directed to the erbB-2 receptor inhibit in vivo tumour cell growthBritish Journal of Cancer, 1993
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu OncogeneScience, 1987